Bioorganic & Medicinal Chemistry Letters 23 (2013) 3505–3510

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Synthesis of novel strobilurin–pyrimidine derivatives and their antiproliferative activity against human cancer cell lines

Baoshan Chai [a,b], Shuyang Wang [a], Wenquan Yu [a], Huichao Li [b], Chuanjun Song [a], Ying Xu [b], Changling Liu [b,*], Junbiao Chang [a,*]

[a] College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, Henan Province 450001, PR China
[b] State Key Laboratory of the Discovery and Development of Novel Pesticide, Shenyang Research Institute of Chemical Industry Co. Ltd, Shenyang, Liaoning Province 110021, PR China

ARTICLE INFO

Article history:
Received 8 November 2012
Revised 10 April 2013
Accepted 18 April 2013
Available online 26 April 2013

Keywords:
Strobilurin–pyrimidine
Antiproliferative activity
Lung cancer
Leukemia
Structure–activity relationship

ABSTRACT

A series of new strobilurin–pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds **I** and **II**. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (**8f**, IC_{50} = 2.2 nM and **11d**, IC_{50} = 3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds **I** and **II** and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin–pyrimidine analogs as potential antitumor agents for the treatment of leukemia.

Strobilurins, isolated from specific fungi, constitute a large family of compounds that possess a broad spectrum of fungicidal activity with low toxicity towards mammalian cells and environmentally benign characteristics.[1,2] Strobilurin derivatives are also used as agrochemical,[1–6] antiviral,[7] anti-malarial,[8] and anti-microbial agents.[9] In particular, the strobilurin–pyrimidine moiety has been extensively utilized as a drug scaffold in medicinal chemistry, and at present, three commercialized fungicide products, including azoxystrobin, fluoxastrobin, and fluacrypyrim, incorporate this substructure (Fig. 1).[1,2,5,6] In addition, it has been found that strobilurin–pyrimidine analogs have antitumor activity through inhibition of STAT3 activation.[10] For example, fluacrypyrim (Fig. 1) inhibited leukemia cancer cell growth by predominantly G1 arrest with significant decreases of cyclin D1 protein and mRNA levels.[10]

Our research group has been investigating the potential of strobilurin–pyrimidine derivatives for antitumor applications. Previously, we discovered two analogs **I** and **II** (Fig. 2), which possess good antiproliferative activity against lung cancer (**I**, IC_{50} = 3.4 μM, **II**, IC_{50} = 3.0 μM, A549) and leukemia (**I**, IC_{50} = 5.5 μM, **II**, IC_{50} = 3.3 μM, HL60) cell lines.[11] As a continuation of our previous work,[11–15] herein we report a follow-up lead optimization to improve the potency, and also structure–activity relationship (SAR) investigation results.

Our structural exploration strategy for the hit compounds (**I** and **II**) is illustrated in Figure 3. For compound **I**, first, the 5-*n*-butyl group was fused with the 6-methyl group on the pyrimidine substructure to form a 5- or six-member carbocycle (**8a**, **8e**) to restrict the possible conformations. Second, a series of halogens and/or alkyl groups (**8b–d**, **8f–g**) was introduced to the 2-phenylamino moiety to study substituent effects on SAR. Similarly, for compound **II**, the phenylamino group was replaced with substituted anilines (**9a–f**) or aliphatic amines (**10a–g**). Next, incorporation of a methyl group at the 5-position of the pyrimidine gave the analog **11** series. Furthermore, replacement of the toxophore (β-methoxyacrylate, Q^1) moiety with groups Q^2–Q^5 afforded derivatives **12–15**.

Key building blocks for the construction of strobilurin–pyrimidine analogs **8–15** were the 2-aminopyrimidin-4-ols **4–7**, which were generally synthesized via condensation of guanidines with the corresponding β-keto esters (Scheme 1). Guanidines **1** and **2** were readily prepared according to our previously reported methods.[14,15] Most of the β-keto esters were purchased from commercial sources, and intermediate **3** was prepared by methylation of ethyl 4,4,4-trifluoro-3-oxobutanoate with methyl bromide.[16] Benzyl halides (**III–V**, Schemes 2 and 3) were prepared according to literature procedures.[17–20] Nucleophilic substitution of the benzyl halides with phenols **4–7** in the presence of potassium carbonate as base afforded the target molecules **8–13** in 65–85% yields (Schemes 2 and 3). The structure of compound **9b** was further confirmed by X-ray crystallography (see 'Supplementary data'). Treatment of

* Corresponding authors.
E-mail addresses: liuchangling@sinochem.com (C. Liu), changjunbiao@zzu.edu.cn (J. Chang).

0960-894X/$ - see front matter © 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmcl.2013.04.045



Figure 1. Structure of representative strobilurin–pyrimidine scaffolds.



Figure 2. Structures of antiproliferative strobilurin–pyrimidine derivatives **I** and **II**.

compounds **12** and **13** with methylamine gave derivatives **14** and **15**, respectively, in good yields (Scheme 3).

The in vitro antiproliferative activity of strobilurin–pyrimidine analogs against two human cancer cell lines (A549 and HL60) was evaluated using MTT or SRB assays according to Mosmann's methods.[21] IC_{50} (μM) values (concentration required to achieve 50% inhibition of tumor growth) of tested compounds are summarized in Tables 1 and 2.

Fusion of the 5-*n*-butyl and 6-methyl groups on the pyrimidine substructure as a 6-member ring (**8a**) did not improve the antiproliferative activity. However, elimination of one ring carbon gave the cyclopenta[*d*]pyrimidine analog (**8e**), which showed equally good or better activity against both cancer cell lines compared to compound **I**. Thus, building on the structure of **8e**, introduction of halogens (**8f–g**) to the aniline moiety was probed to improve potency. For example, the 2,4-dichloro-3-methyl analog (**8g**, IC_{50} = 0.2 μM) led to a 17-fold improvement of activity against the human lung cancer cell line A549 (vs **I**, IC_{50} = 3.4 μM). A breakthrough was the 2,3,4-trifluoro analog (**8f**), which possessed an IC_{50} of 2.2 nM against leukemia cancer cell line HL60. This activity represents an increased potency of 2500-fold better than **I** (IC_{50} = 5.5 μM) and 37-fold greater than doxorubicin (IC_{50} = 0.082 μM), a chemotherapy drug with broad-spectrum antitumor activity. Overall, in this series, substituent effects for the 5- and 6-positions of the pyrimidine ring could be ranked as



Figure 3. Structure exploration strategy based on compounds **I** and **II**.